Clinical Trial Update: EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing EndoTAG-1+GEM versus GEM in locally advanced or metastatic pancreatic adenocarcinoma after FOLFIRINOX failure has completed with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• EndoTAG-1+GEM
• GEM

Snippet

Sponsor: SynCore Biotechnology Co., Ltd. | Conditions: Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-03-24